Alzheimer's research has entered a new phase. The anti-amyloid antibodies have proven that targeting amyloid can slow disease progression—modestly, but credibly—and that success has re-energized the field. But amyloid is no longer the only frontier. Research is broadening to include tau, neuroinflammation, synaptic function, and other mechanisms. The Alzheimer's therapeutic market...
